Literature DB >> 9212839

Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society.

B E Favara1, A C Feller, M Pauli, E S Jaffe, L M Weiss, M Arico, P Bucsky, R M Egeler, G Elinder, H Gadner, M Gresik, J I Henter, S Imashuku, G Janka-Schaub, R Jaffe, S Ladisch, C Nezelof, J Pritchard.   

Abstract

Pathologists and pediatric hematologist/ oncologists of the World Health Organization's Committee on Histiocytic/Reticulum Cell Proliferations and the Reclassification Working Group of the Histiocyte Society present a classification of the histiocytic disorders that primarily affect children. Nosology, based on the lineage of lesional cells and biological behavior, is related to the ontogeny of histiocytes (macrophages and dendritic cells of the immune system). Dendritic cell-related disorders of varied biological behavior are dominated by Langerhans cell histiocytosis, but separate secondary proliferations of dendritic cells must be differentiated. Juvenile xanthogranuloma represents a disorder of dermal dendrocytes, another dendritic cell of skin. The hemophagocytic syndromes are the most common of the macrophage-related disorders of varied biological behavior. Guidelines for distinguishing the exceedingly rare malignant diseases of histiocytes from large cell lymphomas through the use of a battery of special studies are provided.

Entities:  

Mesh:

Year:  1997        PMID: 9212839     DOI: 10.1002/(sici)1096-911x(199709)29:3<157::aid-mpo1>3.0.co;2-c

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  128 in total

1.  Distinctive growth pattern in a patient with a delayed diagnosis of Langerhans' cell histiocytosis.

Authors:  Athanasios D Anastasilakis; Gregory A Kaltsas; Georgios Delimpasis; Ludwig Wilkens; George Kanakis; Polyzois Makras
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

Review 2.  Langerhans' cell histiocytosis: pathology, imaging and treatment of skeletal involvement.

Authors:  E Michel Azouz; Gaurav Saigal; Maria M Rodriguez; Antonello Podda
Journal:  Pediatr Radiol       Date:  2004-07-28

3.  Langerhans' cell histiocytosis in an adult with acute myelogenous leukaemia.

Authors:  Ana Saiz; Miguel A Martinez; Carlos Grande; Francisco Vanaclocha
Journal:  Virchows Arch       Date:  2004-04-22       Impact factor: 4.064

4.  Infection Associated with Hemophagocytic Lymphohisticytosis triggered by nosocomial Infection.

Authors:  J B Gosh; Mahua Roy; Ashok Bala
Journal:  Oman Med J       Date:  2009-07

5.  Langerhans cell histiocytosis with multiple spinal involvement.

Authors:  Liang Jiang; Xiao Guang Liu; Wo Quan Zhong; Qing Jun Ma; Feng Wei; Hui Shu Yuan; Geng Ting Dang; Zhong Jun Liu
Journal:  Eur Spine J       Date:  2010-05-22       Impact factor: 3.134

Review 6.  Rare lung diseases III: pulmonary Langerhans' cell histiocytosis.

Authors:  Stephen C Juvet; David Hwang; Gregory P Downey
Journal:  Can Respir J       Date:  2010 May-Jun       Impact factor: 2.409

7.  Rosai-Dorfman disease (RDD) in the paraglottic space: report of a case and review of literature.

Authors:  Yu-Ling Ma; Zhuo-Ping Liang; Sheng-En Xu; Zhi-Hui Yang; Yi Peng; Xiao-Qiang Sun; Gang Qin
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

8.  An important complication of a child with juvenile idiopathic arthritis: macrophage activation syndrome.

Authors:  Yuvaram N V Reddy; Navin Bhatia; Julius Xavier Scott; Priyathersini Nagarajan
Journal:  BMJ Case Rep       Date:  2013-09-11

9.  Prognostic significance of gelsolin and MMP12 in Langerhans cell histiocytosis.

Authors:  Jong-Jin Seo; Taeshik Cho; Sun-Young Kim; Ibrahim Nassour; Hee-Jin Kim; Yeon-Jung Lim; Kyung-Nam Koh; Ho-Joon Im
Journal:  Korean J Hematol       Date:  2012-12-24

10.  Macrophage activation syndrome in a child with systemic juvenile rheumatoid arthritis.

Authors:  Mina Hur; Young Chul Kim; Kyu Man Lee; Kwang Nam Kim
Journal:  J Korean Med Sci       Date:  2005-08       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.